Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M
Illexcor is developing a first-in-class oral drug that directly targets the root cause of SCD
Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Will add UNLOXCYT (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise
The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara
This addition strengthens Dr. Agarwals Eye Hospital's vast network of 28 hospitals across Karnataka and 220+ facilities worldwide
There are 38.4 million people with diabetes in the United States
Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals
ANVIMO will be available in dosages of 240 mg and 480 mg
Subscribe To Our Newsletter & Stay Updated